HIGHLIGHTS
- who: Per Albertsson from the Shanghai Jiao Tong University, China have published the Article: Astatine-211 based radionuclide therapy: Current clinical trial landscape, in the Journal: (JOURNAL)
- what: This study followed as a natural extension after promising results were obtained using beta-particle-emitting constructs with murine-81C6 in similar clinical situations . Four activity levels were identified: 71-104 MBq (n=5), 135-148 MBq (n=7), 215-248 MBq (n=5), and one patient received 347 MBq. The aim of this dose-escalation study (NCT04461457) was to investigate the safety and pharmacokinetics of 211 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.